Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients with Molecularly-Selected Solid Tumors (ComBET)

The University of Virginia is participating in a clinical research study sponsored by the National Cancer Institute for adults ages 18 and over, who have a solid tumor that has advanced or progressed after treatment with a drug called a PARP inhibitor and your tumor may have abnormalities or changes in the system that repairs damage to your DNA. The purpose of this study is to test the side effects of combining two drugs, called ZEN003694 (ZEN-3694) and talazoparib, as treatment for advanced cancer.

Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT05327010